This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reid, J. M. Articles by Holcenberg, J. Search for Related Content PubMed PubMed Citation Articles by Reid, J. M. Articles by Holcenberg, J. Social Bookmarking                            What's this?

Phase I Trial and Pharmacokinetics of Gemcitabine in Children With Advanced Solid Tumors

From the Mayo Clinic, Rochester, MN; Children's Hospital Medical Center, Seattle, WA; Children's Oncology Group Operations Center, Arcadia; University of Southern California Keck School of Medicine, Los Angeles, CA; Children's National Medical Center, Washington, DC; and Vanderbilt Children's Hospital, Nashville, TN

Address reprint requests to John Holcenberg, MD, Children's Hospital Medical Center, 4800 Sand Point Way NE, Seattle, WA 98105; e-mail: john.holcenberg{at}seattlechildrens.org or jholce{at}yahoo.com

PURPOSE: To determine the maximum tolerated dose, toxicity, and pharmacokinetics of gemcitabine in children with refractory solid tumors.

PATIENTS AND METHODS: Gemcitabine was given as a 30-minute infusion for 2 or 3 consecutive weeks every 4 weeks, to 42 patients aged 1 to 21 years. Doses of 1,000, 1,200 and 1,500 mg/m² were administered for 3 weeks. Subsequently, gemcitabine was given for only 2 consecutive weeks at 1,500, 1,800, and 2,100 mg/m². Plasma concentrations of gemcitabine and its metabolite, 2'2'-difluorodeoxyuridine, were measured in 28 patients.

RESULTS: Forty patients who received 132 courses of gemcitabine were assessable for toxicity. The maximum tolerated dose of gemcitabine given weekly for 3 weeks was 1,200 mg/m². Dose-limiting toxicity was not seen in one-third of children treated at any doses given for 2 weeks. The major toxicity was myelosuppression in three of five patients at 1,500 mg/m² for 3 weeks, and one of seven patients at 1,800 mg/m² for 2 weeks. Other serious adverse events were somnolence, fever and hypotension, and rash in three patients. Gemcitabine plasma concentration–time data were fit to a one- (n = 5) or two-compartment (n = 23) open model. Mean gemcitabine clearance and half-life values were 2,140 mL/min/m² and 13.7 minutes, respectively. One patient with pancreatic cancer had a partial response. Seven patients had stable disease for 2 to 17 months.

CONCLUSION: Gemcitabine given by 30-minute infusion for 2 or 3 consecutive weeks every 4 weeks was tolerated well by children at doses of 2,100 mg/m² and 1,200 mg/m², respectively.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. H. Reddy, H. Khoury, A. Paci, A. Deroussent, H. Ferreira, C. Dubernet, X. Decleves, M. Besnard, H. Chacun, S. Lepetre-Mouelhi, et al. Squalenoylation Favorably Modifies the in Vivo Pharmacokinetics and Biodistribution of Gemcitabine in Mice Drug Metab. Dispos., August 1, 2008; 36(8): 1570 - 1577. [Abstract] [Full Text] [PDF]

				D. P. Lee, J. M. Skolnik, and P. C. Adamson Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct Efficiency J. Clin. Oncol., November 20, 2005; 23(33): 8431 - 8441. [Abstract] [Full Text] [PDF]

				M. Ogawa, H. Hori, T. Ohta, K. Onozato, M. Miyahara, and Y. Komada Sensitivity to Gemcitabine and Its Metabolizing Enzymes in Neuroblastoma Clin. Cancer Res., May 1, 2005; 11(9): 3485 - 3493. [Abstract] [Full Text] [PDF]